Blog

Hedyeh Ebrahimi: Unique challenges that community cancer centers face to engage in oncology clinical trials

Photo taken from Hedyeh Ebrahimi/X

May 9, 2024, 15:31

Hedyeh Ebrahimi: Unique challenges that community cancer centers face to engage in oncology clinical trials

Hedyeh Ebrahimi, Postdoctoral fellow at Genitourinary Cancer Research Team of City of Hope, shared a post on X:

“Hot off the presses JAMA Network Open! We assessed the unique challenges that community cancer centers face to engage in oncology clinical trials in collaboration with The Association of Cancer Care Centers and Genentech under the mentorship of Alex Chehrazi-Raffle.

Hedyeh Ebrahimi

Previous studies have shown most pts with cancer receive care at community centers & willing to participate in clinical trial.However <5% receive care within context of clinical trial. We assessed contributing factors in a national survey among 58 cancer centers from 25 states.

While >90% of centers conducted research studies:

Phase 1 trials were offered less frequently than phase 2or3 trials

Phase 1 trials were offered more frequently at urban and ↑ volume centers

Industry-sponsored trials were more prevalent at academic and ↑ volume centers

79% of cites refer patients for trials, most often due to: – Disease progression or patients request

Most common barriers for referral: – Difficulty in care coordination or lengthy wait times.

Next phase of this study: – Customizing training and admin support to ↑ accessibility, esp in regions historically with ↓ access to clinical trials.

Huge thanks to ACCC for conducting this study and to the cancer centers that participated in this project. Forever grateful to my mentors Alex Chehrazi-Raffle, Sumanta K. Pal and our phenomenal research team

City of Hope.”

Read further.
Source: Hedyeh Ebrahimi/X

Alex Chehrazi-Raffle cancer City of Hope Genentech Hedyeh Ebrahimi JAMA Network Open OncoDaily Oncology Sumanta K. Pal The Association of Cancer Care Centers

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage